

10.1071/HR19016_AC

© CSIRO 2020

Supplementary Material: *Historical Records of Australian Science*, 2020, 31(2), 152–156.

Supplementary Material

David Roderick Curtis 1927–2017

Stephen J. Redman^{A,C} and Robert Porter^B

^AAustralian National University, 62 Kensington Rd, Bolwarra, NSW 2320, Australia.

^BDivision of Tropical Health and Medicine, James Cook University, 21 Tamarind Place, Twin Waters, Qld. 4564, Australia.

^CCorresponding author. Email: steve.redman@anu.edu.au

WORDS IN BOLD PRINT-REPLACE BY GREEK LETTERS

BIBLIOGRAPHY

BIBLIOL

DAVID R CURTIS

1955

1. Pharmacological studies on reflexes. Am. J. Physiol. 183, 106 (with JC Eccles & RM Eccles).
2. Mode of action of tetanus toxin. Nature. 175, 120 (with VB Brooks & JC Eccles).

1956

3. Spinal cord potentials generated by impulses in muscle and cutaneous afferent fibres. J Neurophysiol. 19, 452-467 (with JS Coombs & S Landgren).
4. Time courses of motoneuronal responses. Nature. 178, 1049-1050 (with JS Coombs & JC Eccles).

1957

5. The action of tetanus toxin on the inhibition of motoneurons. J. Physiol. 135; 655-672 (with VB Brooks & JC Eccles).
6. Pharmacological studies on spinal reflexes. J. Physiol. 136, 420-434 (with JC Eccles & RM Eccles).
7. The interpretation of spike potentials of motoneurons. J. Physiol. 139, 198-231 (with JS Coombs & JC Eccles).
8. The generation of impulses in motoneurons. J. Physiol. 139, 232-249 (with JS Coombs & JC Eccles).

1958

9. The excitation of Renshaw cells by pharmacological agents applied electrophoretically. J. Physiol. 141, 435-445 (with RM Eccles).
10. The effect of diffusional barriers upon the pharmacology of cells within the central nervous system. J. Physiol. 141, 446-463 (with RM Eccles).
11. Crossed inhibition of sacral motoneurons. J. Neurophysiol, 21, 319-326 (with K Krnjevic & R Miledi).
12. Gamma-amino-n-butyric acid and spinal synaptic transmission. Nature, 182, 323 (with J W Phillis).

13. Intracellular recording from cells in Clarke's column. Acta physiol.scand.43,303-314 (JC Eccles & A Lundberg).

1959

14. Pharmacological investigations upon inhibition of spinal motoneurones. J.Physiol.145,175-192.
15. The electrical constants of the motoneurone membrane. J.Physiol.145,505-528 (with JS Coombs & JC Eccles).
16. The time courses of excitatory and inhibitory synaptic actions. J.Physiol.145,529-546 (with JC Eccles).
17. Chemical excitation of spinal neurones. Nature.183,611-612 (with J W Phillis & JC Watkins).
18. The depression of spinal neurones by gamma-amino-n-butyric acid and beta-alanine. J Physiol.146,185-203 (with J W Phillis & JC Watkins).

1960

19. The chemical excitation of spinal neurones by certain acidic amino acids. J.Physiol.150,656-682 (with J W Phillis & JC Watkins).
20. The excitation and depression of spinal neurones by structurally related amino acids. J.Neurochem.6,117-141 (with JC Watkins).
21. The excitation of spinal neurones by ionophoretic application of agents which chelate calcium. J.Neurochem.6,1-20 (with JC Watkins & DD Perrin).
22. Investigations upon the possible transmitter function of gamma-aminobutyric acid and naturally occurring amino acids. In: Inhibition of the nervous system and gamma-aminobutyric acid (ed.E Roberts), pp.424-444, Oxford: Pergamon Press (with JC Watkins).
23. Synaptic action during and after repetitive stimulation. J.Physiol.150,374-398 (with JC Eccles).
24. The action of procaine and atropine on spinal neurones. J.Physiol.153,17-34 (with J W Phillis).

1961

25. Chemical transmitter substances in the brain stem of cat. J.Neurophysiol.24,80-90 (with K Koizumi).

26. The effects of drugs and amino acids upon neurones. In: Regional Neurochemistry (eds. S S Kety & J Elkes), pp.403-422, Oxford:Pergamon Press.
27. The identification of mammalian inhibitory transmitters. In: Nervous Inhibitions (ed. E Florey), pp.342-349, Oxford: Pergamon Press.
28. Action of amino-acids on the isolated hemisected spinal cord of the toad. Br.J.Pharmac.16,262-283 (with J W Phillis & J C Watkins).
29. Cholinergic and non-cholinergic transmission in the mammalian spinal cord. J.Physiol.158,296-323 (with J W Phillis & J C Watkins).
30. Analogues of glutamic and gamma-amino-n-butyric acids having potent actions on mammalian neurones. Nature,191,1010-1011 (with J C Watkins).
31. A central action of 5-hydroxytryptamine and noradrenaline. Nature,192,1083-1084 (with R Davis).

1962

32. Direct extracellular application of drugs. Biochem.Pharmac.5,205-212.
33. Pharmacological studies upon neurones of the lateral geniculate nucleus of the cat. Br.J.Pharmac.18,217-246 with R Davis).
34. The action of 3-hydroxytyramine and some tryptamine derivatives on spinal neurones. Nature.194,292.
35. Acetylcholine: a central transmitter? Nature.195,1105-1106 (with P Andersen).
36. The depression of spinal inhibition by electrophoretically administered strychnine. Int.J.Neuropharmac.1,239-250.
37. Central actions of transmitters and the question of chemical transmission at the central synapse. In: Humors, Hormones and Neurosecretion (eds, C McC Brooks, J L Gilbert, HA Levey & DR Curtis), pp.194-219, New York: State University of New York.

1963

38. The excitation of lateral geniculate neurones by quaternary ammonium derivatives. J.Physiol.165,62-82 (with R Davis).

39. Acidic amino acids with strong excitatory actions on mammalian neurones. J.Physiol.166,1-14. (with JC Watkins).
40. Psychotomimetics-a neuropharmacological study. Preec.Aust.Assoc.Neurologists.1,43-45.
41. The pharmacology of central and peripheral inhibition. Pharmac.Rev.15,333-364.
42. Central actions of psychotomimetics. Nature.199,1003-1004 (with R W Ryall).
43. The excitation of cerebellar neurones by acetylcholine. Nature.200,579-580 (with J M Crawford, PE Voorhoeve & V J Wilson).
44. Strychnine and cortical inhibition. Nature.200,843-846 (with J M Crawford, PE Voorhoeve & VJ Wilson).
45. Acetylcholine as a central transmitter. Can.J.Biochem.Physiol.41,2611-2618.

1964

46. Microelectrophoresis. In: Physical Techniques in Biological Research, vol 5 (ed. W L Nastuk), pp.144-190, New York: Academic Press.
47. Action of acetylcholine extracted from brain on spinal Renshaw cells. Nature.201,1034 (with R W Ryall, NE Stone & JC Watkins).
48. The excitation of thalamic neurones by acetylcholine. Acta Physiol.Scand.61,85-99 (with P Andersen).
49. The pharmacology of the synaptic and acetylcholine-induced excitation of ventrobasal thalamic neurones. Acta Physiol.Scand.61,100-120 (with P Andersen).
50. The excitation and depression of mammalian cortical neurones by amino acids. Brit.J.Pharmac.23,313-329 (with J M Crawford).
51. Nicotinic and muscarinic receptors of Renshaw cells. Nature.203,652-653 (with R W Ryall).

1965

52. Actions of drugs on single neurones in the spinal cord and thalamus. Brit.med.Bull.21,5-9.

53. Cholinergic transmission in the mammalian central nervous system. In: Pharmacology of Cholinergic and Adrenergic Transmission (ed. GB Koelle), pp.137-145, Oxford:Pergamon Press (with R W Ryall & JC Watkins).
54. Acetylcholine sensitivity of cerebellar neurones. Nature.206,516-517 (with J M Crawford).
55. The actions of aminoacids upon mammalian neurones. In; Studies in Physiology, Presented to JC Eccles (eds. DR Curtis & AK McIntyre), pp.34-42, Heidelberg:Springer Verlag.
56. Studies in Physiology, Presented to JC Eccles. Edited with AK McIntyre, Heidelberg:Springer Verlag.
57. A central action of hemicholinium. Nature.208,192-194 (with D M J Quastel).
58. The pharmacology of amino acids related to gamma-amino-butyric acid. Pharmac.Rev.17,347-391 (with JC Watkins).

1966

59. Noradrenaline and the inhibition of Renshaw cells. Science,N.Y. 151,1230-1231 (with T J Biscoe).
60. Pharmacological studies upon spinal presynaptic fibres. Expl.Brain Res.1,195-204 (with R W Ryall).
61. Pharmacological studies on thalamic neurones. In: The Thalamus (eds.DP Purpura & MD Yahr), pp.183-191, New York:Columbia University Press.
62. The effect of some psychotomimetic drugs upon single nerve cells. In: Biological Treatment of Mental Illness (ed. M Rinkel), pp.243-261, New York:L C Page & Co.
63. Synaptic transmission in the central nervous system and its pharmacology. In: Nerve as a Tissue (ed. K Rodahl), pp.321-338, New York:Harper & Row.
64. Central effects of beta-N-oxalyl-a,b-diaminopropionic acid and other Lathyrus factors. Nature.211,637 (with JC Watkins & T J Biscoe).
65. The excitation of Renshaw cells by cholinomimetics. Expl.Brain Res.2,49-65 (with R W Ryall).
66. The acetylcholine receptors of Renshaw cells. Expl.Brain Res.2,66-80 (with R W Ryall).

67. The synaptic excitation of Renshaw cells., Expl. Brain Res. 2, 81-96 (with R W Ryall).
68. The action of cholinomimetics on spinal interneurons., Expl. Brain Res. 2, 97-106. (with R W Ryall & JC Watkins).
69. Pharmacological studies on feline Betz cells., J. Physiol. 186, 121-138 (with J M Crawford).
70. Acetylcholine sensitivity of cerebellar neurones in the cat. J. Physiol. 186, 139-165 (with J M Crawford, PE Voorhoeve & VJ Wilson).
71. An investigation of catecholamine receptors of spinal interneurons. Int. J. Neuropharmac. 5, 429-434 (with T J Biscoe & R W Ryall).

1967

72. Strychnine and cortical inhibition. Nature, 214, 914-915 (with T J Biscoe).
73. Glycine and spinal inhibition. Brain Res. 5, 112-114 (with L Hosli, GAR Johnston & I H Johnston).
74. The inhibition of spinal neurones by glycine. Nature. 215, 1502-1503 (with L Hosli & GAR Johnston).
75. Acetylcholine, strychnine and spinal inhibition., Nature. 215, 1503.

1968


76. Pharmacology and neurochemistry of mammalian central inhibitory processes. In: Structure and Function of Inhibitory Neuronal Processes (eds. C Von Euler, S Skoglund & U Soderberg), pp. 429-456, Oxford: Pergamon Press.
77. A method for assembly of "parallel" micro-pipettes., Electroen. clin. Neurophysiol. 24, 587-589.
78. The hyperpolarization of spinal motoneurons by glycine and related amino acids. Expl. Brain Res. 5, 235-258 (with L Hosli, GAR Johnston & I H Johnston).
79. A pharmacological study of the depression of spinal neurones by glycine and related amino acids. Expl. Brain Res. 6, 1-18 (with L Hosli & GAR Johnston).

80. Recent advances in neuropharmacology of neurological interest. Proc.Aust.Assoc.Neurologists.5,101-107.
81. Tetanus toxin and spinal inhibition. Brain Res.10,208-212 (with WC de Groat).
82. Central actions of ibotenic acid and muscimol. Biochem. Pharmac.17,2488-2489 (with GAR Johnston, WC de Groat & AW Duggan).

1969

83. Central synaptic transmission-microelectrophoretic studies. A.Rev.Pharmac.9,209-240 (with J M Crawford).
84. Tetanus toxin and amino acid levels in cat spinal cord. J.Neurochem.16,797-800 (with GAR Johnston & W C de Groat).
85. The pharmacology of spinal postsynaptic inhibition. Prog. Brain Res.31,171-189.
86. The depression of spinal inhibition by morphine. Agents and Actions.1,14-19 (with AW Duggan).
87. Glycine, strychnine, picrotoxin and spinal inhibition. Brain Res.14,759-762 (with AW Duggan & GAR Johnston).
88. On the existence of Renshaw cells. Brain Res.15,597-599 (with AW Duggan).
89. Central synaptic transmitters. In: Basic Mechanisms of the Epilepsies (eds. H H Jasper, AA Ward Jr & A Pope), pp.105-129, Boston:Little, Brown & Co.
90. Amino-acids as central transmitters. Bull.Post-Grad. Commit.Med.Univ.Sydney.Supplement 25,xiv-xxi.

1970

91. Strychnine, glycine, and vertebrate postsynaptic inhibition. Nature.225,1258-1259 (with GAR Johnston).
92. Amino acid transmitters, In: Handbook of Neurochemistry, vol.4 (ed. A Lajtha), pp.115-134, New York:Plenum Press (with GAR Johnston).
93. Central synaptic transmitters. Pre.Aust.Assoc. Neurologists.7,55-59.
- 

94. The inactivation of extracellularly administered amino acids in the feline spinal cord. Expl.Brain Res.10,447-462 (with AW Duggan & GAR Johnston).
95. GABA, bicuculline and central inhibition. Nature.226,1222-1224 (with AW Duggan, D Felix & GAR Johnston).
96. GABA and inhibition of Deiters' neurones. Brain Res.23, 117-120 (with AW Duggan & D Felix).
97. Amino acid transmitters in the mammalian central nervous system. Pree.IV Internat.Cong.Pharmac.1,9-31.
98. Biophysics and the brain. Aust.Bull.Med.Physics Biophys. 46,12-22.
99. Bicuculline and central GABA receptors. Nature.228,676-677 (with AW Duggan, D Felix & GAR Johnston).
100. GABA and hippocampal inhibition. Br.J.Pharmac.40,881-883 (with D Felix & H McLennan).

1971

101. Tetanus toxin as a pharmacological tool. In: Neuropoisons, Their Pathophysiological Actions vol. 1 (ed. LL Simpson), pp.263-281, New York:Plenum Press.
102. The specificity of strychnine as a glycine antagonist in the mammalian spinal cord. Expl.Brain Res.12,547-565 (with AW Duggan & GAR Johnston).
103. GABA and prolonged spinal inhibition. Nature,New Biology. 231,187-188 (with D Felix).
104. Bicuculline, an antagonist of GABA and synaptic inhibition in the spinal cord of the cat. Brain Res.32,69-96 (with AW Duggan, D Felix & GAR Johnston).
105. Antagonism between bicuculline and GABA in the cat brain. Brain Res.33,57-73 (with AW Duggan, D Felix, GAR Johnston & H McLennan).
106. The effect of bicuculline upon synaptic inhibition in the cerebral and cerebellar cortices of the cat. Brain Res.34,301-321 (with D Felix).
107. Amino acid antagonists. Experientia.27,1110.
108. 4-Aminotetrolic acid: A new conformationally-restricted analogue of gamma-butyric acid. Nature,New Biology. 234,80-81 (with PM Beart & GAR Johnston).

109. Muscarinic action of acetylcholine. Nature.234,355 (with D Felix).
110. Neutral amino acids as central transmitters. The use of amino acid antagonists. In: Research in Physiology. A Liber Memorialis in Honour of Professor Chandler McCuskey Brooks (eds.FF Kao, K Koizumi & M Vassalle), PP.403-411, Bologna:Aulo Gaggi.
111. Effect of intracellular injection of pyridine nucleotides on electrical responses of cat spinal motoneurons. Brain Res.35,570-572 (with JC Watkins & D Felix).

1972

112. Morphine and the synaptic excitation of Renshaw cells. Neuropharmac.11,189-196 (with AW Duggan).
113. gamma-Aminobutyrylcholine and central inhibition. J.Pharm. Pharmac.24,251-252 (with GAR Johnston).
114. Excitation of mammalian central neurones by acidic amino acids. Brain Res.41,283-301 (with AW Duggan, D Felix, GAR Johnston, AK Tebecis & JC Watkins).
115. Convulsive action of penicillin. Brain Res.43,242-245 (with CJ A Game, GAR Johnston, RM McCulloch & R M Maclachlan).
116. Microelectrophoretic studies of single neurones In: Experimental Models of Epilepsy (eds.DP Purpura, J K Penry, D Tower, D M Woodbury & T Walter), pp.249-268, New York:Raven Press.
117. Bicuculline methochloride as a GABA antagonist. Nature, New Biology.240,219-220 (with GAR Johnston, PM Beart, C J ³/₄ Game, RM McCulloch & RM Maclachlan).
118. Bicuculline and thalamic inhibition. Expl.Brain Res.16, 210-218 (with AK Tebecis).

1973

119. Bicuculline, GABA and central inhibition. Proc.Aust.Soc. Neurologists.9,145-153.
120. Antagonism of neuronal excitation by 1-hydroxy-3-amino-pyrrolidone-2. Brain Res.49,467-470 (with GAR Johnston, CJ A Game & RM McCulloch).
121. Tetanus toxin and the synaptic release of GABA. Brain Res.51,358-362 (with D Felix, CJ A Game & RM McCulloch).

122. Central actions of shikimin and tutin. Brain Res.63,419-423 (with J Davies, CJ A Game, GAR Johnston & R M McCulloch).
123. Configuration of bicuculline, a GABA antagonist. Nature, New Biology.246,190 (with GAR Johnston).

1974

124. Amino acid transmitters in the mammalian central nervous system. Ergebn.Physiol.69,97-188 (with GAR Johnston).
125. Central effects of beta-(p-chlorophenyl)-gamma-aminobutyric acid. Brain Res.70,493-499 (with CJ A Game.GAR Johnston &RM McCulloch).
126. Spinal interneurone excitation by conformationally restricted analogues of L-glutamic acid. Nature.248,804-805. (with GAR Johnston, J Davies & RM McCulloch).
127. Convulsant alkaloids. In: Neuropoisons, vol 2, Poisons of Plant Origin (eds.LL Simpson & DR Curtis), pp.207-248 New York:Plenum Press (with GAR Johnston).
128. Central action of bicuculline. J.Neurochem.23,605-606 (with GAR Johnston, CJ A Game & RM McCulloch).
129. Antagonism of inhibitory amino acid action by tubocucarine. Br.J.Pharmac.52,101-103 (with CJ A Game & RM McCulloch).
130. Amino acid neurotransmitters and the brain. Med.J.Aust. 1974.2,723-731.
131. The differential sensitivity of spinal interneurons and Renshaw cells to kainate and N-methyl-D-aspartate. Expl. Brain Res.21,515-518 (with RM McCulloch, CJ A Game & G A R Johnston).

1975

132. Cis- and trans-4-aminocrotonic acid as GABA analogues of restricted conformation. J.Neurochem.24,157-160 (with GAR Johnston, PM Beart, CJ A Game, RM McCulloch & B Twitchin).
133. Gamma-aminobutyric and glutamic acids as mammalian central transmitters. In: Metabolic Compartmentation and Neurotransmission (eds. S Berl, DD Clarke & D Schneider), pp.11-36, New York:Plenum Press.

134. Structure and biological activity of a series of conformationally restricted analogues of GABA. J. Neurochem. 25, 803-809 (with P Krogsgaard-Larsen, GAR Johnston, CJ A Game & RM McCulloch).

1976

135. The use of transmitter antagonists in microelectrophoretic investigations of central synaptic transmission. In: Drugs and Central Synaptic Transmission (eds. PB Bradley & B N Dhawan), pp. 7-35, London: Macmillan]
136. Benzodiazepines and central glycine receptors. Br. J. Pharmac. 56, 307-311 (with CJ A Game & D Lodge).
137. The in-vivo inactivation of GABA and other inhibitory amino acids in the cat nervous system. Expl. Brain Res. 25, 413-428 (with CJ A Game & D Lodge).
138. A pharmacological study of Renshaw cell inhibition. J. Physiol. 258, 227-242 (with CJ A Game, D Lodge & RM McCulloch).
139. Central actions of benzodiazepines. Brain Res. 118, 344-347 (with D Lodge, G R Johnston & SJ Brand).
140. Chemical transmitters in the central nervous system. Bull. Post-Grad. Commit. Med. Univ. Sydney. 32, 182-195.

1977

141. Dual effects of hemicholinium-3 at central cholinergic synapses. J. Physiol. 264, 367-377 (with CR Craig & D Lodge).
142. Some aspects of the clinical neuropharmacology of amino acid neurotransmitters. In: Neurotransmitter Function: Basic and Clinical Aspects (ed. WS Fields), pp. 163-183, Symposia Specialists: Miami, Florida.
143. Phosphonic analogues as antagonists of amino acid excitants. J. Pharm. Pharmac. 29, 324 (with JC Watkins and S J Brand).
144. Central actions of amino-oxyacetic acid. Brain Res. 129, 181-182 (with D Lodge).
145. A pharmacological study of the inhibition of ventral group Ia-excited spinal interneurons. Expl. Brain Res. 29, 97-105 (with D Lodge & S J Brand).
146. GABA and spinal afferent terminal excitability in the cat. Brain Res. 130, 360-363 (with D Lodge & SJ Brand).

147. A new class of GABA agonist. Nature.268,53-55 (with P Krogsgaard-Larsen, GAR Johnston & D Lodge).
148. Effects of the Areca nut constituents arecaidine and guvacine on the action of GABA in the cat central nervous system. Brain Res.136,513-522- (with D Lodge, GAR Johnston & SJ Brand).
149. Pentobarbitone enhancement of the inhibitory action of GABA. Nature.270,533-544 (with D Lodge).
150. Spinal transmitters: A brief review. In: Proc. Far East and South Pacific Spinal Cord Conference, pp.117-123.

1978

151. GABA depolarization of spinal group I afferent terminals. In: Iontophoresis and Transmitter Mechanisms of the Mammalian Central Nervous System (eds. R W Ryall & JS Kelly), pp.258-260, Elsevier/North Holland Biomedical Press (with D Lodge).
152. Bicuculline-sensitive GABA agonists. In: Iontophoresis and Transmitter Mechanisms of the Mammalian Central Nervous System (eds. R W Ryall & JS Kelly), pp,372-374, Elsevier/North Holland Biomedical Press (with GAR Johnston, P Krogsgaard-Larsen & D Lodge).
153. In vivo correlates of in vitro GABA uptake inhibition in cat CNS. In: Iontophoresis and Transmitter Mechanisms of the Mammalian Central Nervous System (eds. R W Ryall & JS Kelly), pp.378-380, Elsevier/North Holland Biomedical Press (with D Lodge & GAR Johnston).
154. Pre- and non-synaptic activities of GABA and related amino acids in the mammalian nervous system. In: Amino Acids as Chemical Transmitters (ed. F Fonnum), pp.55-86, New York:Plenum Press.
155. Time course of GABA and glycine actions on cat spinal neurones; effect of pentobarbitone. Neurosci.Letts.8, 125-129 (with D Lodge).
156. Amino acid neurotransmitters. Proc.Aust.Physiol.Pharmac.Soc.9, 99-103.
157. Selective antagonism by D-a-amino adipate of amino acid and synaptic excitation of cat spinal neurones. Brain Res.152,603-608 (with D Lodge & PM Headley).

158. Does uptake limit the action of GABA agonists in vivo? Experiments with muscimol, isoguvacine and THIP in cat spinal cord. J. Neurochem. 31, 1525-1528 (with D Lodge & G A R Johnston).
159. Gabergic transmission in the mammalian central nervous system. In: GABA-Neurotransmitters (eds. H Kofod, P Krosggaard-Larsen & JScheel-Kruger), pp.17-27, Copenhagen:Munksgaard.
160. Pre- and postsynaptic action of GABA in the mammalian spinal cord. In: Advances in Pharmacology and Therapeutics, 2, Neurotransmitters (ed. P Simon), pp.281-298, Oxford: Pergamon Press.

1979

161. Problems in the evaluation of glutamate as a central nervous system transmitter. In: Glutamic Acid: Advances in Biochemistry and Physiology (eds. L J Filer, S Garratini, MR Kare, WA Reynolds & R J Wurtman), pp.163-175, New York:Raven Press.
162. Electrical interaction between motoneurons and afferent terminals in cat spinal cord. J. Neurophysiol. 42, 635-641 (with D Lodge & PM Headley).
163. Dihydromuscimol, thiomuscimol and related heterocyclic compounds as GABA analogues. J. Neurochem. 32, 1717-1724 (with P Krosggaard-Larsen, H Hjeds, D Lodge & GAR Johnston).
164. The excitation and depression of spinal neurones by ibotenic acid. J. Physiol. 291, 19-28 (with D Lodge & H McLennan).
165. A method for continuously monitoring the electrical threshold of single intraspinal nerve fibres. Electroen. Neurophysiol. 47, 503-506.
166. Kainate neurotoxicity and glutamate inactivation. Neurosci. Letts. 14, 343-348 (with D Lodge, GAR Johnston & JC Bornstein).
167. Nuciferine and central glutamate receptors. J. Pharm. Pharmacol. 31, 795-797 (with D Lodge & JC Bornstein).

1980

168. Potentiation of L-glutamate and L-aspartate excitation of cat spinal neurones by the stereoisomers of threo-3-hydroxyaspartate. J.Neurochem.34,241-243 (with D Lodge, GAR Johnston & JC Bornstein).
169. In vivo inactivation of quisqualate: studies in the cat spinal cord. Brain Res.182,491-495 (with D Lodge, GAR Johnston & JC Bornstein).
170. Selective antagonist activity of 5-aminohex-2-enedioic acid on amino acid excitation of cat spinal neurones. Neurosci.Letts.16,17-20 (with RD Allan, JC Bornstein, GAR Johnston & D Lodge).
171. A new class of glutamate agonist structurally related to ibotenic acid. Nature.284,64-66 (with P Krogsgaard Larsen, T Honore, J J Hansen & D Lodge).
172. The synthesis and activity of cis and trans-2-(aminomethyl) cyclopropanecarboxylic acid as conformationally restricted analogues of GABA. J.Neurochem.34,652-656 (with RD Allan, PM Headley, GAR Johnston, D Lodge & B Twitchin).
173. Piperidine-4-sulphonic acid, a new specific GABA agonist. J.Neurochem.34,756-759 (with P Krogsgaard-Larsen, E Falch, A Schousboe & D lodge).
174. Cyclobutane analogues of GABA. Neurochem.Res.5,393-400 (with RD Allan, PM Headley, GAR Johnston, SM E Kennedy, D Lodge & B Twitchin).
175. In vivo analysis of GABA receptors on primary afferent terminations in the cat. Brain Res.194,255-258 (with JC Bornstein & D Lodge).

1981

176. Structure-activity studies on ibotenic acid and related muscimol analogues. In: Glutamate as a Neurotransmitter (eds, G Di Chiara & G L Gessa), pp.285-294, New York: Raven Press (with P Krogsgaard-Larsen, T Honore, J J Hansen & D Lodge).
177. Selective effects of (-)-baclofen on spinal synaptic transmission in the cat. Expl.Brain Res.42,158-170 (with D Lodge, JC Bornstein & M J Peet).

1982

178. The depolarization of feline ventral horn group la spinal afferent terminations by GABA. Expl.Brain Res.46,215-233 (with D Lodge).
179. Lack of specificity of a 'taurine antagonist'. Brain Res. 244,198-199 (with JD Leah & M J Peet).
180. Glutamic acid agonists. Stereochemical and conformational studies of DL-alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) and related compounds. Neurosci. Letts.31,313-317 (with P Krogsgaard-Larsen, J J Hansen, J Lauridsen, M J Peet & JD Leah).
181. In vivo and in vitro effects of pentobarbitone sodium. J.Pharm.Pharmacol.34,686 (with M Willow, M J Peet & G A R Johnston).
182. Glycine antagonists structurally related to muscimol, TRIP or isoguvacine. J.Neurochem.39,1319-1324 (with P Krogsgaard-Larsen, H Hjeds, JD Leah & M J Peet).
- 183 The dual effects of GABA and related amino acids on the electrical threshold of ventral horn group la afferent terminations in the cat. Expl.Brain Res.48,387-400 (with D Lodge, JC Bornstein, M J Peet & JD Leah).
184. Central neurotransmitters:current concepts. In: Topics in Child Neurology, Vol 2 (eds.GB Wise, ME Blaw & PG Procopis), pp.95 107, New York:Spectrum Puhl.Inc.

1983

185. Effects of noradrenaline and 5-hydroxytryptamine on spinal la afferent terminations. Brain Res.258,328-332 (with JD Leah & M J Peet).
186. Post-excitatory depression of neuronal firing by acidic amino acids and acetylcholine in the cat spinal cord. Brain Res.263,162-166 (with M J Peet & R Malik).
187. Antagonists of synaptic and amino acid excitation of neurones in the cat spinal cord. Brain Res.266,83-95 (with M J Peet & JD Leah).
188. 4,5,6,7-Tetrahydroisothiazolo[S,4-c]pyridin-3-ol and related analogues of TRIP. Synthesis and biological activity. J.Med.Chem.26,895-900 (with P Krogsgaard-Larsen, H Mikkelsen, P Jacobsen, E Falch, M J Peet & JD Leah).

189. Spinal interneurone depression by DS 103-282. Br J. Pharmac. 79, 9-11 (with JD Leah & M J Peet).
190. Molecular pharmacology of the GABA receptors and GABA agonists. In: CNS Receptors- From Molecular Pharmacology to Behaviour (eds, P Mandel & F V DeFeudis), pp.1-13, New York: Raven Press (with P Krosggaard-Larsen, E Falch, M J Peet & JD Leah).
- 191 Gabergic transmission in the spinal cord. Pre. Aust. Physiol. Pharmac. Soc. 14, 69-82.
192. Actions of midazolam in the spinal cord of the cat. Neuropharmac. 22, 1349-1356 (with JD Leah & R Malik).

1984

193. The effect of GABA on the terminations of vestibulospinal neurones in the cat spinal cord. Brain Res. 295, 372-375 (with VJ Wilson and R Malik).
194. Depolarization of feline primary afferent fibres by acidic amino acids. J. Physiol. 351, 461-472 (with PM Headley & D Lodge).
195. Ibotenic acid analogues. Synthesis and biological and in vitro activity of conformationally restricted agonists at central excitatory amino acid receptors. J. Med. Chem. 27, 585-591 (with P Krosggaard-Larsen & E O Nielsen).
196. The effects of naloxone, morphine and methionine enkephalinamide on Ia afferent terminations in the cat spinal cord. Brain Res. 303, 289-298 (with R Malik & JD Leah).
197. Ethylene diamine: a GABA mimetic? Trends Pharmacol. Sci. 5, 458 (with R Malik).
198. The effect of GABA on lumbar terminations of rubrospinal neurons in the cat spinal cord. Proc. R. Soc. Lond. B 223, 25-33 (with R Malik).

1985

199. GABA-mimetic activity and effects on diazepam binding of aminosulphonic acids structurally related to piperidine-4-sulphonic acid. J. Neurochem. 44, 68-75 (with E Falch, P Jacobsen & P Krosggaard-Larsen).
200. Securinine alkaloids: A new class of GABA receptor antagonist. Brain Res. 330, 135-140 (with JA Beutler, E W Karban, AN Brubaker, R Malic & SJ Enna).

201. Glycine antagonism by RU5135. Eur.J.Pharmac.110,383-384. (with R Malik).
202. The differential effects of baclofen on segmental and descending excitation of spinal interneurons in the cat. Expl.Brain Res.58,333-337 (with R Malik).
203. The micropharmacology of spinal terminals. (In Japanese), Seitai No Kagaku 36,69-78.
204. Synthesis and structure-activity studies on excitatory amino acids structurally related to ibotenic acid. J.Med.Chem.28,673-679. (with P Krogsgaard-Larsen, L Brehm, J/ S Johansen, P Vinzents & J Lauridsen).
205. A neurophysiological analysis of the effect of kainic acid on nerve fibres and terminals in the cat spinal cord. J.Physiol.368,99-108 (with R Malik).
206. Synthesis, GABA agonist activity and effects on GABA and diazepam binding of some N-substituted analogues of GABA. Eur.J.Med.Chem.20,447-453 (with E Falch, P Krogsgaard-Larsen, P Jacobsen, A Engesgaard & C Braestrup}
207. GABA agonists. R solution, absolute stereochemistry, and enantioselectivity of (S)-(+)- and (R)-(-)-dihydromuscimol. J.Med.Chem.28,1612-1617 (with P Krogsgaard-Larsen, L Nielsen & E Falch).

1986

208. GABA agonists and uptake inhibitors. Stereoselectivities and anticonvulsant effects. In: Neurotransmitters, Seizures and Epilepsy III (ed. G Nistico et al.), pp.135-150, New York:Raven Press. (with P Krogsgaard-Larsen, E Falch & A Schousboe)
209. Glycine antagonists. Synthesis, structure and biological effects of some bicyclic 5-isoxazolol zwitterions. J Med. Chem,29,224-229 (with L Brehm, P Krogsgaard-Larsen, K Schaumburg, JS Johansen & E Falch).
210. Ibotenic acid analogues. Synthesis and biological testing of two bicyclic 3-isoxazolol amino acids. Acta Chem.Scand. B 40,92-97 (with U Madsen, K Schaumburg, L Brehm & P Krogsgaard-Larsen).
211. Pyridazinyl-GABA derivatives as GABA and glycine antagonists in the spinal cord of the cat. Neurosci.Letts. 68,211-215 (with B D Gynther).

212. A pharmacological study of group I muscle afferent terminals and synaptic excitation in the intermediate nucleus and Clarke's column of the cat spinal cord. Expl.Brain Res.64,105-113 (with B D Gynther & R Malik).
213. On the probable absence of GABA receptors on the terminations of motor axon collaterals in the cat spinal cord. Expl.Brain Res.64,114-118 (with B D Gynther).
214. Pitrazepin: a central glycine and GABA antagonist. Eur.J.Pharmac.131,311-313 (with B D Gynther).

1987

215. Phaclofen: a peripheral and central baclofen antagonist. Brain Res.405,150-154 (with DI B Kerr, J Ong, RH Prager & B D Gynther).
216. Synthesis and biological activity of a GABA-A agonist which has no effect on benzodiazepine binding and some structurally related glycine antagonists. Drug Design Delivery.1,261-274 (with JR Byberg, IM Labouta, E Falch, H Hjeds & P Krogsgaard-Larsen).
217. Ouabain and the membrane transport of amino acids and amines. Neurochem.Res.12,755-757.
218. Divalent cations reduce depolarization of primary afferent terminations by GABA. Brain Res.422,192-195 (with B D Gynther).

1988

219. Molecular pharmacology of excitatory amino acid receptors: conformational and stereochemical requirements. In: Pharmacology (eds. M J Rand & C Raper), pp.113-116, Elsevier Science Publishers BV (with P Krogsgaard-Larsen, U Madsen, B Nielsen, J J Hansen, E O Nielsen & L Brehm).
220. Baclofen antagonism by 2-hydroxy-saclofen in the cat spinal cord. Neurosci.Letts.92,97-101 (with B D Gynther, D T Beattie, DI B Kerr & RH Prager).

1989

221. Post-tetanic influences on primary afferent depolarization in the cat spinal cord. Expl.Brain Res.74,365-374 (with B D Gynther).

222. Baclofen antagonism by 4-amino-3-(5-methoxybenzo[b]furan-2-yl)butanoic acid in the cat spinal cord. Neurosci.Letts. 100,292-294 (with D T Beattie, M Debaert, C Vaccher & P Berthelot).
223. Excitatory amino acid agonists. Enzymic resolution, X-ray structure, and enantioselective activities of (R)- and (S)-bromohomoibotenic acid. J.Med.Chem.32,2254-2260 (with J J Hansen, B Nielsen, P Krogsgaard-Larsen, L Brehm & E O Nielsen).
224. Amino acid neuromediators (in Russian). Pharmacology and Toxicology.52,4-18.

1990

225. Synthesis and single cell pharmacology of potential heterocyclic bioisosters of the excitatory amino acid antagonist glutamic acid diethyl ester. Acta Chem.Scand.B. 44,96-102 (with U Madsen, E O Neilsen, D T Beattie & P Krogsgaard-Larsen).
226. Micropharmacology of central synaptic terminals. Proc.Aust.Neurosci.Soc.1,8-9.

1991

227. Novel class of amino acid antagonists at non-N-methyl-D-aspartic acid excitatory amino acid receptors. Synthesis, in vitro and in vivo pharmacology, and neuroprotection. J.Med.Chem.34,123-130 (with P Krogsgaard-Larsen, J W Ferkany, E O Neilsen, U Madsen, B Ebert, JS Johansen, NH Diemer, T Bruhn and D T Beattie).
228. Novel gamma-amino-butyric acid-A agonists and partial antagonists. In: Transmitter Amino Acid Receptors: Structures, Transduction and Models for Drug Development (eds.EA Barnard & E Costa), pp.237-249 (with P Krogsgaard-Larsen, B Frolund, U Kristiansen & JDC Lambert).

1993

229. Enzymatic resolution of AMPA by use of alpha-chymotrypsin. Bioorg.Med.Chem.Letts.3;107-114 (with B Nielsen, H Fisker, B Ebert, U Madsen, P Krogsgaard-Larsen & J J Hansen).
230. Thienyl-GABA derivatives as specific baclofen agonists in the rat and cat spinal cord in vivo. Neurosci.Letts. 159,64-66 (with G Lacey, P Berthelot, C Vaccher, N Flouquet, MP Vaccher & M Debaert).

1994

231. GABA-B receptor-mediated spinal inhibition. NeuroReport, 5, 540-542 (with GLacey).
232. Phosphinic acid derivatives as baclofen agonists and antagonists in the mammalian spinal cord: an in vivo study. Expl.Brain Res.101,59-72 (with G Lacey).
233. Differing actions of nitroprpane analogs of GABA and baclofen in central and peripheral preparations. Eur.J. Pharmac.264,49-54 (with J Ong, DI BKerr, G Lacey, R Hughes & RH Prager).

1995

234. Inhibitory amino acids as spinal transmitters. Clin.Expl. Pharmac.Physiol.22,A1.
235. GABA synapses in brain. Trends Neurosci.18,263.
236. An in vivo electrophysiological investigation of group Ia afferent fibres and ventral horn terminations in the cat spinal cord. Expl.Brain Res.106,403-417 (with B D Gynther, D T Beattie & G Lacey).

1997

237. Baclofen: reduction of presynaptic calcium influx in the cat spinal cord in vivo. Expl.Brain Res.113,520-533 (with B D Gynther, G Lacey & D T Beattie).
238. The lack of effect of baclofen on action potentials of spinal motor axon collateral terminations in vivo. Expl.Brain Res.114,184-187 (with G Lacey).
239. Two types of inhibition in the spinal cord. In: Presynaptic Inhibition and Neural Control. (eds. P Rudomin, R Romo & LMMendell), pp, 150-161, Oxford University Press.
240. Sir John Eccles-Neuroscientist. Expl.Brain Res.116,1-2.
241. Sir John Eccles. Endeavour,21,139-140.
242. Sir John Carew Eccles, 1903-1997.Proc.Aust.Physiol.Pharmac. Soc.28(2),vii-ix.

1998

243. Sir John Eccles: Neuroscientist. Proc.Aust.Neurosci.Soc.9,v-vi.

244. Prolonged GABA-B receptor-mediated synaptic inhibition in the cat spinal cord: an in vivo study. Expl.Brain Res. 121,319-333 (with G Lacey).
245. John Carew Eccles. Obituary Notice. Aust.Acad.Sci.Year Book 1998-1999,pp.90-92 (with P Andersen).

2001

246. John Carew Eccles. 1903-1997. Hist.Rec.Aust.Sci.13,439-473 (with P Andersen).
247. Sir John Carew Eccles,A.C. Biog.Mems.Fell.R.Soc.Lond. 47,159-187 (with Per Andersen).
248. The John School of Medical Research. The first fiftv years, 1948-1998. (with F Fenner) Gundaroo:Brolga Press.

2002

249. Sir John Eccles, AC-Nobel Laureate. Melbourne University Magazine.2002 Edition,28-29.

2003

250. Mentors in Neuroscience. John Carew Eccles, Nobel Laureate (1903-1997). J.Clin.Neurosci.10,171-173.
251. Sir John Eccles. 1903-1997. Chiron.5,54.

2006

252. David R. Curtis. In:The History of Neuroscience in Autobiography. (ed. LR Squire) vol 5, pp.169-225. Amsterdam: Elsevier.